Cannara Biotech Inc (LOVE) Fair Value & Analysis
Healthcare · CA · Market cap C$166M
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from C$2.91 to C$2.65 (−8.9%) since Jun 23, 2026. Share price +1.8% over the past month.
Price vs Fair Value (5 months)
5‑month range C$1.51 – C$1.93 · fair‑value band C$1.84 – C$3.31 · the C$1.60 price screens below the C$2.65 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Cannara Biotech Inc (LOVE) currently trades at C$1.60, while our model-based Fair Value estimate is C$2.65 — implying the stock looks roughly 65.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Cannara Biotech Inc generated revenue of C$113M at a net margin of 9.0%. Revenue grew 2.6% year over year. It earns a return on equity of 9.5%. Net debt stands at C$27.2M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cannara Biotech Inc reported revenue of C$107M in FY2025 versus C$17.0M in FY2021, a compound +58.5%/yr. Reported net income was C$13.1M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥26.59 | -46% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cannara Biotech Inc (LOVE) undervalued?
What is the fair value of LOVE?
What is the quality score of LOVE?
What is the revenue of Cannara Biotech Inc (LOVE)?
What is the net profit margin of LOVE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.